Ricoh Europe: 84 per cent of consumers prepared to take action over irrelevant and non-personalised communications
The inundation of irrelevant communications and junk mail is pushing European consumer loyalty to breaking point with the majority (84 per cent) ready to take action against brands, according to new research commissioned by Ricoh Europe.
Irrelevant communications, both online and paper-based, are a huge bug-bear for more than two-thirds of consumers in Europe, who consider a quarter of what they receive to be junk. Six-in-ten consumers even see junk mail as more frustrating than their commute to work.
Beyond the mere frustration factor, consumers are suffering negative consequences from being unable to sift through the flood of irrelevant information and poor quality comms. A quarter (25 per cent) have missed a payment deadline, and over a third have been unsure how much they owe for a service (34 per cent) or missed offers they were entitled to (39 per cent).
Brands need to beware that irrelevant communications are having a significantly detrimental impact on customer loyalty, trust and spend, and consumers are unafraid to bite back. Two-thirds (65 per cent) of consumers report feeling less loyal to a brand spamming with irrelevant information, whilst a similar number would also spend less (63 per cent) and even go so far as to stop being a customer completely (57 per cent). Nearly a fifth of consumers have moved their custom elsewhere, another fifth have complained to a service provider, and 1-in-10 have taken their complaint to an authoritative body.
David Mills, CEO of Ricoh Europe, said: “When it comes to the irrelevance and volume of communication sent out by brands and service providers, consumers are clearly saying enough is enough. It’s never been easier to communicate instantly with customers, but in the digital age, it’s likewise never been easier to spam. Brands need to tread carefully not to scupper the effectiveness of vital communication channels. With severe penalties in place for getting it wrong and consumers ready to walk away, hitting the right note at the right time is key. An increasingly competitive business landscape, an influx of highly ambitious start-ups and the simple fact that customers expect more from providers, means the need for quality, customised communications – both digital and paper-based – has never been greater.”
A majority of consumers (64 per cent) believe more could be done to tailor communications to their individual circumstances. 8-in-10 would even be willing to share personal data to make this happen, including occupation, salary, Internet browsing habits and health records.
Consumers also increasingly view digital communications as their preferred method to receive information from brands and service providers: for new offers and upgrades (74 per cent), statements and bills (67 per cent) and updates to terms and conditions (64 per cent).
Mills continues: “Consumers want to feel like a company has taken the time to get to know them as an individual and stop bombarding them with both confusing and meaningless information. The appropriate use of consumers’ data is critical for this. No matter whether they have a preference for digital communications – such as online bank statements – or a mix of electronic and paper-based, there’s no excuse not to use this insight to ensure communications are bespoke, which in turn makes them genuinely effective.”
The industries viewed as currently sending the most relevant communications to consumers are the public sector (42 per cent), financial services (39 per cent), utilities (37 per cent) and healthcare (36 per cent). With the exception of utilities, these industries were similarly seen to be the most trustworthy handlers of customer data. However, no single sector is viewed positively by more than half of consumers, which goes to show significant work still needs to be done by brands across all industries to bring confidence in their customer communications up to scratch.
“To do this, businesses need to streamline how they collect, distribute and manage data to ensure its consistent use across all channels. Information provided by customers setting-up their account or store-cards, for example, should be used to create promotional offers and updates that are not only personal to the individual, but also highly relevant to their circumstances. This results in the customer feeling valued, which ultimately drives loyalty and benefits to the business,” concludes Mills.
Find out more at www.ricoh-europe.com/thoughtleadership .
| About Ricoh |
Ricoh is a global technology company specializing in office imaging equipment, production print solutions, document management systems and IT services. Headquartered in Tokyo, Ricoh Group operates in about 200 countries and regions. In the financial year ending March 2015, Ricoh Group had worldwide sales of 2,231 billion yen (approx. 18.5 billion USD).
The majority of the company's revenue comes from products, solutions and services that improve the interaction between people and information. Ricoh also produces award-winning digital cameras and specialized industrial products. It is known for the quality of its technology, the exceptional standard of its customer service and sustainability initiatives.
Under its corporate tagline, imagine. change. Ricoh helps companies transform the way they work and harness the collective imagination of their employees.
For further information, please visit www.ricoh-europe.com
Ricoh Europe PLC
Tel: +44 (0) 203 033 3766
Join us on Facebook: www.facebook.com/ricoheurope
Follow us on Twitter: www.twitter.com/ricoheurope
Visit the Ricoh media centre at: www.ricoh-europe.com/press
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom